Recent Updates
Recently added Catalysts
KURA Positive Sentiment Score: 70/100

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Monday, December 2, 2024 1 min read
Key Takeaway: Kura Oncology, a clinical-stage biopharmaceutical company, has announced a virtual investor event scheduled for December 9, 2024. The event will discuss the KOMET-007 combination trial of its oral menin inhibitor, ziftomenib, following updates presented at the 66th American Society of Hematology Annual Meeting. Key members of the management team, along with trial investigators, will be present to engage with investors. Access to the event will be available via phone and webcast.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kura Oncology is committed to precision medicines for cancer treatment.
  • The company is presenting updated clinical data at a prominent medical meeting.
  • The virtual investor event indicates active engagement with investors.

Full Press Release Details

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at 8:00 a.m. ET / 5:00 a.m. PT on Monday, December 9, 2024, to discuss the KOMET-007 combination trial of the Company’s oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego.
The virtual event will feature members of the management team along with investigators from the KOMET-007 trial. The live call may be accessed by dialing (800) 715-9871 for domestic callers and (646) 307-1963 for international callers and entering the conference ID: 4326549. A live webcast will be available here and in the Investors section of Kura’s website, with an archived replay available shortly after the event.
Executive Vice President, Investor Relations &
Corporate Communications
pete@kuraoncology.com
cassidy.mcclain@inizioevoke.com

Frequently Asked Questions

When is Kura Oncology's virtual investor event?

The virtual investor event is on December 9, 2024, at 8:00 a.m. ET.

What trial will Kura Oncology discuss in the event?

Kura will discuss the KOMET-007 combination trial of ziftomenib.

How can I access the virtual investor event?

Access the event via phone at (800) 715-9871 or through a live webcast.

Who will participate in the virtual event?

Management team members and investigators from the KOMET-007 trial will participate.

Is there a replay available after the event?

Yes, an archived replay will be available shortly after the event.

Tags: KURA Viatris Investor Conferences Healthcare Kura Oncology ziftomenib KOMET-007 ASH Annual Meeting cancer treatment
Last updated: Dec 2, 2024